Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.

NCT Number	NCT06385236
Lead Sponsor	University of California, San Diego Collaborators: Mayo Clinic, Yale University, University of Arizona, Harvard University, Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Moderate to Severe Asthma
Enrollment	120 participants
Start Date	2024-02-19
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-01-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-19